Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cygnus GlucoWatch

This article was originally published in The Gray Sheet

Executive Summary

Large-scale manufacturing of the non-invasive glucose monitoring system's consumable AutoSensor component by supplier Corium gains FDA approval via PMA supplement, Cygnus announces Aug. 7. The company plans to perform final assembly of the wristwatch-like monitor at its own manufacturing facility to reduce costs, and plans to file a related PMA supplement. The device was approved in March and a full-scale launch is expected by year-end (1"The Gray Sheet" March 26, 2001, p. 13)

You may also be interested in...

Cygnus GlucoWatch Pilot Marketing Program To Begin In April

Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.

UK Grants First Worldwide Authorization For PfIzer/BioNTech COVID-19 Vaccine

The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Wockhardt Preps To Deliver 100M Doses Of AZ Vaccine

As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts